Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients.
OBJECTIVE
Copper is an essential mineral nutrient for humans. Serum copper levels of hemodialysis patients are higher than those of healthy subjects, but it remains to be elucidated whether increased serum copper may have harmful effects. In addition, a recent in vitro study has shown that sevelamer can adsorb copper. In the present study, we searched for clinical factors associated with serum copper levels in hemodialysis patients.


METHODS
This cross-sectional study included patients undergoing hemodialysis for more than 6 months. In these patients, we statistically tested associations between serum copper levels and other parameters, including nutritional markers, lipid profiles, oxidative stress, inflammation, and sevelamer administration.


RESULTS
Among 48 patients (male/female = 28:20, age 71 ± 10 years, hemodialysis duration 84 ± 72 months), sevelamer hydrochloride was administered in 39 patients (81.3 %). In univariate analysis, serum copper levels showed significant positive correlations with serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde modified-LDL and negative correlations with plasma total homocysteine levels and the administered dose of sevelamer. In multivariate analysis, serum levels of LDL-cholesterol and hs-CRP were found to be independent determinants of serum copper levels.


CONCLUSIONS
We found that serum copper levels were independently associated with dyslipidemia and inflammation in hemodialysis patients, but the pathogenic roles of copper remain to be elucidated. In addition, potential effect of sevelamer on serum copper levels should be examined in appropriately designed studies.
Department of Nephrology and Dialysis, H. N. Medic Kitahiroshima, 5-6-1 Kyoeicho, Kitahiroshima, Hokkaido, 061-1113, Japan. i-key@hnmedic.jp
Ryota
R
Ikee
Masataka
M
Tsunoda
Naomi
N
Sasaki
Naritsugu
N
Sato
Nobuo
N
Hashimoto
D000368:Aged; D002614:Chelating Agents / Q000627:therapeutic use; D003300:Copper / Q000097:blood*; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D011073:Polyamines / Q000008:administration & dosage*; D006435:Renal Dialysis / Q000009:adverse effects*; D000069603:Sevelamer; D013997:Time Factors
D002614:Chelating Agents; D011073:Polyamines; D003300:Copper; D000069603:Sevelamer